Literature DB >> 15856509

Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.

Zheng Huang1, Qun Chen, David Luck, Jill Beckers, Brian C Wilson, Nadira Trncic, Susan M Larue, Dominique Blanc, Fred W Hetzel.   

Abstract

BACKGROUND AND OBJECTIVES: Photodynamic therapy (PDT) mediated with Tookad (Pd-bacteriopheophorbide, WST09) was investigated pre-clinically as part of a program to develop an alternative modality for treating prostate cancer. STUDY DESIGN/
MATERIALS AND METHODS: Spontaneous canine prostate cancer and normal canine prostate were used as the animal models. Interstitial PDT was performed by IV infusion of the photosensitizer and irradiating the prostates with a diode laser (763 nm). The prostates were harvested 1-week post-PDT and subjected to histopathologic examinations. The effects of the drug doses and light doses were studied for one- and two-session PDT. Pharmacokinetics were studied using HPLC assay. The feasibility of using perfusing CT scans for assessing PDT lesions was also evaluated.
RESULTS: Tookad is a vascular-acting drug and clears rapidly from the circulation. Tookad-PDT-induced lesions, in both normal and cancerous prostates, were characterized by marked hemorrhagic necrosis.
CONCLUSIONS: Tookad-PDT is very effective in ablating prostatic tissue through its vascular effects. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856509      PMCID: PMC1201403          DOI: 10.1002/lsm.20177

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  36 in total

1.  Effects of photodynamic therapy on peripheral nerve: in situ compound-action potentials study in a canine model.

Authors:  Kenneth C Dole; Qun Chen; Fred W Hetzel; Lawrence R Whalen; Dominique Blanc; Zhen Huang
Journal:  Photomed Laser Surg       Date:  2005-04       Impact factor: 2.796

2.  Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.

Authors:  Qun Chen; Zheng Huang; David Luck; Jill Beckers; Pierre-Herve Brun; Brian C Wilson; Avigdor Scherz; Yoram Salomon; Fred W Hetzel
Journal:  Photochem Photobiol       Date:  2002-10       Impact factor: 3.421

3.  Indirect detection of photosensitizer ex vivo.

Authors:  Ludovic Bourré; Sonia Thibaut; Amélie Briffaud; Nathalie Rousset; Sabine Eléouet; Youenn Lajat; Thierry Patrice
Journal:  J Photochem Photobiol B       Date:  2002-05       Impact factor: 6.252

4.  Photodynamic therapy in the canine prostate using motexafin lutetium.

Authors:  R A Hsi; A Kapatkin; J Strandberg; T Zhu; T Vulcan; M Solonenko; C Rodriguez; J Chang; M Saunders; N Mason; S Hahn
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

Review 5.  Photodynamic therapy in oncology.

Authors:  C H Sibata; V C Colussi; N L Oleinick; T J Kinsella
Journal:  Expert Opin Pharmacother       Date:  2001-06       Impact factor: 3.889

6.  Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate.

Authors:  S H Selman; D Albrecht; R W Keck; P Brennan; S Kondo
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450

7.  Antivascular treatment of solid melanoma tumors with bacteriochlorophyll-serine-based photodynamic therapy.

Authors:  J Zilberstein; S Schreiber; M C Bloemers; P Bendel; M Neeman; E Schechtman; F Kohen; A Scherz; Y Salomon
Journal:  Photochem Photobiol       Date:  2001-03       Impact factor: 3.421

Review 8.  Laser dosimetry studies in the prostate.

Authors:  Q Chen; F W Hetzel
Journal:  J Clin Laser Med Surg       Date:  1998-02

9.  Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients.

Authors:  Robert A Weersink; Jason Forbes; Stuart Bisland; John Trachtenberg; Mostafa Elhilali; Pierre H Brún; Brian C Wilson
Journal:  Photochem Photobiol       Date:  2005 Jan-Feb       Impact factor: 3.421

10.  Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study.

Authors:  Timothy R Nathan; Douglas E Whitelaw; Stanley C Chang; William R Lees; Paul M Ripley; Heather Payne; Linda Jones; M Constance Parkinson; Mark Emberton; Alison R Gillams; Anthony R Mundy; Stephen G Bown
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

View more
  15 in total

Review 1.  A review of progress in clinical photodynamic therapy.

Authors:  Z Huang
Journal:  Technol Cancer Res Treat       Date:  2005-06

2.  Effects of photodynamic therapy on peripheral nerve: in situ compound-action potentials study in a canine model.

Authors:  Kenneth C Dole; Qun Chen; Fred W Hetzel; Lawrence R Whalen; Dominique Blanc; Zhen Huang
Journal:  Photomed Laser Surg       Date:  2005-04       Impact factor: 2.796

3.  Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland.

Authors:  Zheng Huang; Masoom A Haider; Susan Kraft; Qun Chen; Dominique Blanc; Brian C Wilson; Fred W Hetzel
Journal:  Lasers Surg Med       Date:  2006-08       Impact factor: 4.025

4.  The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues--in vivo study in a canine model.

Authors:  Zheng Huang; Qun Chen; Kenneth C Dole; Al B Barqawi; Yang K Chen; Dominique Blanc; Brian C Wilson; Fred W Hetzel
Journal:  Photochem Photobiol Sci       Date:  2007-08-22       Impact factor: 3.982

Review 5.  The future of lasers in urology.

Authors:  Sean A Pierre; David M Albala
Journal:  World J Urol       Date:  2007-06-14       Impact factor: 4.226

Review 6.  Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight.

Authors:  Andrzej M Bugaj
Journal:  World J Methodol       Date:  2016-03-26

7.  Myocardial necrosis depth prediction during extracellular photosensitization reaction of talaporfin sodium by defined index using fluorescence measurement.

Authors:  M Takahashi; A Ito; T Kimura; S Takatsuki; K Fukuda; T Arai
Journal:  Lasers Med Sci       Date:  2013-12-07       Impact factor: 3.161

8.  Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release.

Authors:  Denise Bechet; Loraine Tirand; Béatrice Faivre; François Plénat; Corinne Bonnet; Thierry Bastogne; Céline Frochot; François Guillemin; Muriel Barberi-Heyob
Journal:  Pharm Res       Date:  2010-01-20       Impact factor: 4.200

Review 9.  Combination of photodynamic therapy and immunomodulation: current status and future trends.

Authors:  Yong-Gang Qiang; Christine M N Yow; Zheng Huang
Journal:  Med Res Rev       Date:  2008-07       Impact factor: 12.944

10.  A pilot trial of vascular targeted photodynamic therapy for renal tissue.

Authors:  Surena F Matin; Peggy T Tinkey; Agatha T Borne; L Clifton Stephens; Avigdor Sherz; David A Swanson
Journal:  J Urol       Date:  2008-05-22       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.